Advaxis, Inc. (ADXS) CFO Sara Bonstein Sells 12,734 Shares
Advaxis, Inc. (NASDAQ:ADXS) CFO Sara Bonstein sold 12,734 shares of the business’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total transaction of $40,621.46. Following the sale, the chief financial officer now directly owns 244,504 shares in the company, valued at $779,967.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Advaxis (NASDAQ:ADXS) last posted its quarterly earnings data on Monday, September 11th. The biotechnology company reported ($0.80) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.27). The business had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $3.43 million. Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/02/advaxis-inc-adxs-cfo-sara-bonstein-sells-12734-shares.html.
Several analysts have issued reports on the stock. ValuEngine downgraded shares of Advaxis from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 3rd. BidaskClub downgraded shares of Advaxis from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Cantor Fitzgerald reissued a “buy” rating and set a $19.00 target price on shares of Advaxis in a research note on Monday, September 25th. Finally, HC Wainwright reissued a “buy” rating and set a $23.00 target price on shares of Advaxis in a research note on Friday, September 15th.
Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Advaxis by 9.2% in the first quarter. Vanguard Group Inc. now owns 1,663,010 shares of the biotechnology company’s stock valued at $13,587,000 after buying an additional 139,710 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Advaxis by 4.8% in the first quarter. Geode Capital Management LLC now owns 279,812 shares of the biotechnology company’s stock worth $2,286,000 after acquiring an additional 12,736 shares during the last quarter. Swiss National Bank boosted its stake in shares of Advaxis by 17.5% in the first quarter. Swiss National Bank now owns 55,800 shares of the biotechnology company’s stock worth $456,000 after acquiring an additional 8,300 shares during the last quarter. OxFORD Asset Management LLP acquired a new stake in shares of Advaxis in the second quarter worth approximately $498,000. Finally, Tudor Investment Corp ET AL acquired a new stake in shares of Advaxis in the first quarter worth approximately $283,000. Institutional investors and hedge funds own 48.02% of the company’s stock.
Advaxis Company Profile
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.